+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.

Age: 18Years +All GendersPhase 3
140 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.

Age: 18Years +All GendersPhase 3
68 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the dermatological and ophthalmological safety of a cosmetic product in adults with oily or acne-prone skin aged 18 to 45 years. The study aims to determine if the product lacks comedogenic and acnegenic potential, is well tolerated on the skin and eyes, and presents a low risk of irritation or discomfort during normal use. Participants will apply the moisturizing cream to their face and body twice daily for 28 days. Throughout the study, clinical dermatological and ophthalmological assessments will be performed to monitor skin and eye acceptability, as well as to evaluate the products potential to cause acne or comedones. During the 28-day study period, participants will attend scheduled visits for evaluations including clinical skin examination and slit-lamp eye assessments. Researchers will measure comedogenic and acnegenic potential at the start and end of the study, along with signs of skin irritation and ocular tolerability. The study plans to enroll 33 participants and monitor their response to the product under normal conditions of use.

Age: 18Years - 45YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the dermatological safety and effectiveness of a moisturizing cream in adults aged 35 to 65 years who have moderate to severe dryness xerosis on their lower legs. The study aims to determine if the product is well tolerated without causing irritation, improves skin hydration after single and repeated use, enhances skin barrier recovery and strength, and how participants perceive its performance. Participants will apply the moisturizing cream twice daily to their lower limbs for 28 days. The study includes clinical skin evaluations and instrumental assessments using devices called Corneometerae to measure skin hydration and Tewameterae to assess skin barrier function. Questionnaires will also be completed to capture participants views on the products performance and efficacy. During the study, participants will undergo dermatological assessments at baseline and after 28 days to evaluate skin acceptability. Skin hydration and barrier function will be measured at multiple time points after single and repeated applications. Participants will complete questionnaires on perceived product effectiveness. The study lasts 28 days with regular monitoring to track skin condition and product tolerance.

Age: 35Years - 65YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the effectiveness of Finlndia hair lotion combined with oral treatment for men with androgenetic alopecia, a common form of hair loss. This Phase III clinical trial aims to compare this investigational lotion with a combination of minoxidil lotion and finasteride pills to understand which treatment better improves hair density. The study is sponsored by EMS and uses a randomized, double-blind, double-dummy design to ensure unbiased results. Participants will be assigned to one of two groups. One group will take an oral placebo pill and apply 1 mL of Finlndia hair lotion twice daily. The other group will take one oral finasteride pill daily and apply 1 mL of minoxidil lotion twice daily. This treatment period lasts six months, during which participants will follow these dosing schedules closely. During the study, participants hair density changes will be measured after six months to evaluate treatment effects. Researchers will also monitor and record any adverse events to assess safety. The study involves regular visits for assessments and adherence monitoring. The total participation time is six months, after which participants will complete the study evaluations.

Age: 18Years - 60YearsMALEPhase 3
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness of a depigmenting gel cream called Blancy Pro in reducing facial hyperpigmentation and improving skin appearance. This clinical study involves 40 female participants aged 30 to 60 years who have either facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, or moderate to severe melasma. The study is designed to assess the products impact through clinical, subjective, and instrumental evaluations over a 90-day period. Participants are randomly assigned into two groups one with diverse Fitzpatrick skin phototypes I to VI experiencing various types of hyperpigmentation, and the other with moderate or greater melasma and Fitzpatrick skin phototypes II to V. All participants will apply the depigmenting gel cream daily for 90 days. The study includes assessments at baseline, and on days 14, 30, 60, and 90 to monitor changes in pigmentation, skin tone, hydration, pH, barrier function, and participant perception. Throughout the 90-day study, participants will attend scheduled on-site visits for clinical evaluations, instrumental skin measurements, and questionnaires. Researchers will measure changes in facial hyperpigmentation using a chromameter, modified Melasma Area and Severity Index, VISIA imaging, and skin hydration instruments. Safety and participant-reported outcomes on efficacy and quality of life will also be monitored. The sponsor of this trial is Brainfarma Industria Qumica e Farmacutica SA.

Age: 30Years - 60YearsFEMALEPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the safety and topical effectiveness of a scar gel used continuously for 90 days. The study compares this investigational scar gel to a benchmark product to see how well each prevents hypertrophic scars and improves scar appearance. The research also examines effects on skin hydration, itching, discomfort, and scar pigmentation normalization. Participants will be randomly assigned to use either the investigational scar gel or the benchmark scar gel. Both products are health care devices applied topically to recent scars. The study is double-blinded to ensure unbiased results. The treatment period lasts 90 days, during which participants apply the products as directed. During the study, participants will attend scheduled visits for evaluations to monitor scar appearance and skin condition. Researchers will collect clinical assessments and participant perceptions throughout the 90-day period. The main outcome measured is the clinical and perceived efficacy of the scar gels after 90 days of use. Safety and skin hydration will also be monitored to understand the overall effects of the products.

Age: 18Years - 70YearsAll GendersPhase 1Phase 2
2 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness of a daily Fiber Nutritional Supplement called Maternaae Opti fiber, which contains partially hydrolyzed guar gum PHGG and vitamins C, D, zinc, and selenium, combined with nutritional counselling. This study focuses on managing constipation during pregnancy, a common gastrointestinal issue that can affect quality of life and well-being. The trial is open label and single arm, enrolling pregnant women between 13 and 27 weeks of gestation who meet specific criteria for functional constipation. Participants will receive one sachet per day of the fiber supplement providing about 5.8 grams of PHGG for 4 weeks. In addition to the supplement, all participants will get standardized constipation counselling at the start, which includes education on constipation and lifestyle advice. This study involves a single group receiving this combined intervention. Throughout the study, participants will be monitored for changes in stool frequency from baseline to 4 weeks. Researchers will also assess stool consistency, symptoms of constipation and gut discomfort, healthcare and medication use related to constipation, and product acceptance. Participants will complete questionnaires in English and are expected to comply with study requirements, including avoiding other fiber or probiotic supplements during the intervention period.

Age: 21Years +FEMALEPhase Not Applicable
1 location

1-10 of 11

1